Relapsing Multiple Sclerosis (RMS) Pipeline Insight, 2018 Report - ResearchAndMarkets.com
Aug. 23, 2018
DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The "Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
'Relapsing Multiple Sclerosis (RMS) - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Relapsing Multiple Sclerosis (RMS) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the report:The report provides a snapshot of the pipeline development for the Relapsing Multiple Sclerosis (RMS) The report covers pipeline activity across the complete product development cycle, i.e. clinical, pre-clinical and discovery stages for the Relapsing Multiple Sclerosis (RMS) The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Relapsing Multiple Sclerosis (RMS) The report also covers the dormant and discontinued pipeline projects related to the Relapsing Multiple Sclerosis (RMS)
Key Topics Covered:
1. Report Introduction
2. Relapsing Multiple Sclerosis (RMS) Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic Assessment
8. Inactive Products
Companies MentionedAbbVie Inc. Actelion Ltd BIOCAD Cognosci F. Hoffmann-La Roche Ltd. Genzyme Corporation Merck KGaA Pfenex Inc. Receptos VivaCell Biotechnology Espana S.L.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3w55ng/relapsing?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005489/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/23/2018 10:13 AM/DISC: 08/23/2018 10:13 AM